XML 100 R84.htm IDEA: XBRL DOCUMENT
v3.24.0.1

License and Other Agreements (Details) € in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | 240 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2020 USD ($) | Apr. 30, 2020 | Oct. 31, 2016 USD ($) | Jul. 31, 2014 | Feb. 28, 2014 USD ($) kg | Apr. 30, 2008 EUR (€) | Dec. 31, 2016 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2009 USD ($) | Dec. 31, 2004 USD ($) | Dec. 31, 2023 USD ($)
PARI Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  |  |  | 15 years |  |  |  |  |  |  |
Additional term of contract manufacturing agreement |  |  |  | 5 years |  |  |  |  |  |  |
PARI Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  |  |  | 1 year |  |  |  |  |  |  |
PARI Agreement | Milestone, New Drug Application |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
PARI milestone upon FDA approval | € |  |  |  |  |  | € 1.0 |  |  |  |  |
PARI Agreement | Milestone, FDA Approval |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
PARI milestone upon FDA approval | € |  |  |  |  |  | 1.5 |  |  |  |  |
PARI Agreement | Milestone, EMA Approval |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
PARI milestone upon FDA approval | € |  |  |  |  |  | € 0.5 |  |  |  |  |
PPD Development, L.P. Agreement |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of clinical development services agreement |  | 5 years |  |  |  |  |  |  |  |  |
Written notice termination term of clinical development services agreement |  | 30 days |  |  |  |  |  |  |  |  |
License Agreement with AstraZeneca |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, additional payment |  |  |  |  |  |  | $ 12.5 |  |  |  |
Royalty payment |  |  | $ 35.0 |  |  |  |  |  |  |  |
License Agreement with AstraZeneca | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Aggregate payment upon the achievement of certain clinical milestones |  |  | 60.0 |  |  |  |  |  |  |  |
Additional contingent payments upon second indication to develop INS1007 |  |  | 42.5 |  |  |  |  |  |  |  |
License Agreement with AstraZeneca | License and Service |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Annual net sales |  |  | $ 1,000.0 |  |  |  |  |  |  |  |
License Agreement with AstraZeneca | Research and development expenses |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 30.0 |  |  |  |
Phase 3 study payment | $ 12.5 |  |  |  |  |  |  |  |  |  |
Resilience Biotechnologies |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Initial term of contract manufacturing agreement |  |  |  |  | 5 years |  |  |  |  |  |
Written notice period required for termination of contract manufacturing agreement |  |  |  |  | 2 years |  |  |  |  |  |
Manufacturing scale (in kilograms) | kg |  |  |  |  | 200 |  |  |  |  |  |
Period of each automatic renewal of contract manufacturing agreement |  |  |  |  | 2 years |  |  |  |  |  |
Minimum obligation |  |  |  |  | $ 6.0 |  |  |  |  |  |
CFFT |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements |  |  |  |  |  |  |  |  |  |  |
Compensation earned under research funding agreements with CFFT |  |  |  |  |  |  |  |  | $ 2.2 | $ 1.7 |
Royalty payable on approval of ARIKAYCE as commercialized drug |  |  |  |  |  |  |  | $ 13.4 |  |  | $ 13.4
Royalty expense paid for ARIKAYCE approval |  |  |  |  |  |  |  |  |  |  | 7.4
Period for meeting sales milestones for additional royalty payments |  |  |  |  |  |  |  | 5 years |  |  |
Royalty payable on meeting certain sales milestones |  |  |  |  |  |  |  | $ 3.9 |  |  | $ 3.9
Additional global sales milestone payments |  |  |  |  |  |  |  | $ 1.7 |  |  |

X
- Definition Additional Royalty Expense + References No definition available. + Details
Name: | insm_AdditionalRoyaltyExpense
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of royalty payments if entity meets certain milestones under a research and development agreement. + References No definition available. + Details
Name: | insm_AdditionalRoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the additional extension period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_AdditionalTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate additional series of contingent milestone payments if selects to develop for second indication. + References No definition available. + Details
Name: | insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Additional Payment + References No definition available. + Details
Name: | insm_CollaborativeArrangementAdditionalPayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Milestone Payment + References No definition available. + Details
Name: | insm_CollaborativeArrangementMilestonePayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Phase 3 Study Payment + References No definition available. + Details
Name: | insm_CollaborativeArrangementPhase3StudyPayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of upfront payment paid during the period under collaborative arrangement. + References No definition available. + Details
Name: | insm_CollaborativeArrangementUpfrontPayment
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the minimum obligation due under the terms of the agreement. + References No definition available. + Details
Name: | insm_CommercialServicesAgreementMinimumObligation
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contract Manufacturing Agreement, Rate Of Manufacturing + References No definition available. + Details
Name: | insm_ContractManufacturingAgreementRateOfManufacturing
Namespace Prefix: | insm_
Data Type: | dtr-types:massItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial Term of Clinical Development Services Agreement + References No definition available. + Details
Name: | insm_InitialTermOfClinicalDevelopmentServicesAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the initial period of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_InitialTermOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate payment upon the achievement of certain clinical milestones. + References No definition available. + Details
Name: | insm_PaymentsUponAchievementOfClinicalMilestonesAmount
Namespace Prefix: | insm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period for meeting sales milestones for additional royalty payments after the drug is commercialized. + References No definition available. + Details
Name: | insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period of each automatic renewal of contract manufacturing agreement. + References No definition available. + Details
Name: | insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the written notice period required for termination of contract manufacturing agreement by either party. + References No definition available. + Details
Name: | insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written Notice Termination Term Of Clinical Development Services Agreement + References No definition available. + Details
Name: | insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement
Namespace Prefix: | insm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount the entity has committed to make for future royalty guarantees. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483119/928-440-50-1 + Details
Name: | us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | insm_MilestonePaymentAxis=insm_MilestoneEMAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_PPDDevelopmentLPAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |